High levels of CD47 have indeed been observed in both lymphoid and myeloid neoplasms, in which this factor is both an adverse prognostic indicator and a valid anti-cancer target with several therapeutic antibodies currently being tested in clinical trials. Here, CD47 is linked to cancer.